目的：提高对抗体叠加中枢神经系统炎性脱髓鞘疾病（inflammatory demyelinating disorder，IDD）的认识。

方法：报道1例先后出现视神经炎及颅内多发病灶的43岁男性患者，结合文献复习，探讨抗髓鞘少突胶质细胞糖蛋白抗体（anti-myelin oligodendrocyte glycoprotein antibody，MOG-ab）叠加抗髓鞘碱性蛋白抗体（anti-myelin basic protein antibody，MBP-ab）介导的中枢神经系统IDD的临床表现和可能的发病机制。

结果：尽管有广泛的颅内病变和视野缺损，该患者在接受血浆置换术后恢复良好，免疫抑制治疗未见短期复发。

结论：MOG-ab叠加MBP-ab抗体鲜有报道，其致病机制不明，诊断主要依据抗体检测。因此，当怀疑中枢神经系统IDD时，尽早完善中枢神经系统脱髓鞘抗体谱的检测至关重要，有利于早期诊断和治疗，减少功能残疾。

Objective: To improve the clinical cognition of antibodies overlapping inflammatory demyelinating disease (IDD) in the central nervous system (CNS).

Methods: A 43-year-old male case of optic neuritis followed by multiple intracranial lesions successively is reported. The clinical manifestations and possible pathogenesis of demyelinating diseases mediated by anti-myelin oligodendrocyte glycoprotein (MOG-ab) and anti-myelin basic protein (MBP-ab) are discussed based on literature review.

Results: Despite extensive intracranial lesions and visual field defects, the patient recovered well after plasmapheresis, and there was no short-term recurrence in immunosuppressive therapy.

Conclusion: Therefore, when CNS-IDD are considered, it is important to detection of CNS demyelinating antibodies for early diagnosis, treatment and reduce functional disability.